ASCO GU 2026: Updates in metastatic prostate cancer
Dr George Follows (Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK) talks with Dr Andrew Zelenetz (Memorial Sloan Kettering Cancer Centre, New York, USA) at the BSH conference in Glasgow.
Comparing first line schemes between USA and UK CLL treatment, with specific regard to the recent RESONATE-2 trial of frontline ibrutinib, they discuss toxicity, cost and combination of available treatments.
This video is supported by an educational grant from Gilead.
ASCO GU 2026: Updates in metastatic prostate cancer
ASCO GU 2026: Updates in localised prostate cancer
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Tele-mentoring: Impact of project ECHO
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting